AngioDynamics, Inc. (NASDAQ:ANGO) (�AngioDynamics�), a leading
provider of medical devices for the diagnosis and treatment of
peripheral vascular diseases and other non-coronary diseases, and
RITA Medical Systems, Inc. (NASDAQ:RITA) (�RITA�), a leading
provider of medical oncology devices, today announced the signing
of a definitive agreement whereby AngioDynamics will acquire RITA
for approximately $220 million plus the assumption of approximately
$3.3 million in net debt. The transaction will create a
world-class, diversified medical technology company with a broad
line of access, diagnostic and therapeutic products that enable
interventional physicians and surgeons to treat peripheral vascular
diseases and cancerous tumors. Excluding transaction-related and
one-time integration expenses, AngioDynamics expects this
acquisition to be neutral to its fiscal year 2007 (ending June 2,
2007) earnings and to add approximately $0.05 per share to its
fiscal year 2008 (ending May 31, 2008) diluted GAAP EPS assuming
25.8 million weighted average diluted shares outstanding. The
Boards of Directors of both companies unanimously approved the
acquisition, which is anticipated to close by the end of the first
calendar quarter of 2007, subject to regulatory review, the
approval of each company�s respective shareholders and other
customary closing conditions. �This business combination is about
growth, leadership and long-term value creation. The combination of
AngioDynamics and RITA will create a leader in serving the needs of
interventional radiologists, vascular surgeons and other medical
specialties with a compelling product portfolio of exciting
technologies,� said Eamonn P. Hobbs, President and Chief Executive
Officer of AngioDynamics. �Interventional oncology is a large and
growing area for our existing customer base, and RITA�s leadership
position, premium products and excellent reputation fit our
strategy perfectly.� �RITA�s talented 33-person U.S. sales force
targets the same customer base as does AngioDynamics� 52-person
U.S. sales force and the companies have virtually no product
overlap,� added Mr. Hobbs. �RITA has a very strong position in
vascular access ports, which are an ideal sales fit with our
Morpheus� CT PICC and the vascular access port technology we
purchased from Medron last May. In addition, our recently acquired
irreversible electroporation (IRE) soft tissue ablation technology,
which AngioDynamics expects to commercialize in mid-2008, will be
complementary to RITA�s diverse offering of local oncology
therapies, which include its market-leading radiofrequency ablation
systems, Habib Sealer� resection devices and LC Beads� for tumor
embolization.� �Once the merger of our two companies is complete,
the current RITA sales organization will remain intact and will
focus on maximizing the opportunity for RITA�s radiofrequency
thermal tumor ablation products and oncological surgical devices.
The current AngioDynamics sales force will take on responsibility
for RITA�s specialty access catheter business, which we believe
will be a seamless transition. We also look forward to leveraging
RITA�s 10-person direct sales force in the U.K., Germany and France
to sell AngioDynamics� products.� Mr. Hobbs continued, �With
respect to financial performance, for the 52-weeks ended August 31,
2006 the two organizations recognized more than $132 million in
combined pro forma revenues. While we intend to keep RITA�s
experienced sales, marketing, R&D and operational teams
virtually intact, we anticipate cost savings of at least $9 million
annually from the elimination of duplicate public company,
corporate and certain trade-show expenses. In addition, we expect
to receive cash tax benefits exceeding $30 million in aggregate
over the next 16 years from the utilization of RITA�s federal net
operating loss carry-forwards. We expect this cash tax benefit to
be approximately $1.8 million for the fiscal year ending June 2,
2007, $7.1 million for the fiscal year ending May 31, 2008 and $7.1
million for the fiscal year ending May 30, 2009. Clearly, this is
an outstanding business opportunity for AngioDynamics from both
strategic and financial perspectives, with very low integration
risks,� concluded Mr. Hobbs. Joseph DeVivo, President and Chief
Executive Officer of RITA Medical Systems, said, �AngioDynamics has
established itself as a leader in developing, manufacturing and
marketing innovative products for the diagnosis and treatment of
peripheral vascular diseases, and has earned the respect of
interventional radiologists and vascular surgeons for its
commitment to its customers. The transaction creates compelling
value for the RITA shareholders today and into the future as RITA
shareholders will become significant equity owners of AngioDynamics
and participate in its future success. I believe having RITA become
a part of AngioDynamics is the best way to continue the vision of
creating a successful�franchise in medical device oncology.�
Acquisition Terms Under the terms of the merger agreement, each
common share of RITA will be exchanged for (i) 0.1722 (the
�Exchange Ratio�) of an AngioDynamics common share and (ii) a
specified amount of cash based on AngioDynamics� average closing
stock price for the 10-day period ending three business days prior
to the date of the shareholder meetings (the �ANGO Stock Price�).
If the ANGO Stock Price is between $18.18 and $27.29 per share,
each common share of RITA will receive an amount of cash such that
the total stock and cash consideration is equal to $4.70 per RITA
share. If the ANGO Stock Price is below $18.18 per share, RITA
common shareholders will receive the equity consideration and $1.57
in cash per RITA share. If the ANGO Stock Price is greater than
$27.29 per share, RITA shareholders will receive only the equity
consideration. All RITA outstanding options and warrants will be
exercisable for the same consideration payable to RITA common
shareholders upon exercise of the option or warrant. Based on the
Exchange Ratio, AngioDynamics expects to issue approximately 7.86
million common shares in the transaction and to issue an additional
approximately 1.91 million common shares upon exercise of RITA
options and warrants. Upon closing the transaction, it is
anticipated that RITA security holders will own approximately 34.5%
of AngioDynamics on a fully diluted treasury stock method basis.
The transaction is intended to qualify as a tax-free
reorganization. Following the closing of the transaction, the Board
of Directors of AngioDynamics will include three members of the
current RITA Board of Directors. Cain Brothers & Company, LLC
acted as exclusive financial advisor to AngioDynamics. Skadden,
Arps, Slate, Meagher & Flom LLP is acting as legal counsel to
AngioDynamics in this transaction. Piper Jaffray & Co. acted as
lead financial advisor and C.E. Unterberg, Towbin, LLC acted as
co-financial advisor to RITA in connection with the transaction.
Heller Ehrman LLP is acting as legal counsel to RITA in this
transaction. Conference Call and Presentation AngioDynamics and
RITA management will host a conference call including slide
presentation to discuss this announcement today, November 28
beginning at 11:30 a.m. Eastern time. To participate in the call,
please dial (800) 798-2801 from the U.S. or (617) 614-6205 from
outside the U.S. The passcode is 72096391. Slides that accompany
management's presentation will be available at
http://investor.angiodynamics.com/. A telephone replay of the call
will be available from 1:30 p.m. Eastern time on November 28, 2006
through 11:59 p.m. Eastern time on November 30, 2006 by dialing
(888) 286-8010 (domestic) or (617) 801-6888 (international) and
entering conference ID number 36392819. In addition, individuals
can listen to the call by visiting the investor relations portion
of the AngioDynamics web site at
http://investor.angiodynamics.com/. A recording of the call, along
with the slide presentation, will be archived there for 12 months.
About AngioDynamics AngioDynamics, Inc. is a leading provider of
innovative medical devices used by interventional radiologists,
vascular surgeons and other physicians for the minimally invasive
diagnosis and treatment of peripheral vascular disease.
AngioDynamics designs, develops, manufactures and markets a broad
line of therapeutic and diagnostic devices that enable
interventional physicians, such as interventional radiologists,
vascular surgeons and others, to treat peripheral vascular diseases
and other non-coronary diseases. The company's diverse product line
includes angiographic products and accessories, dialysis products,
vascular access products, PTA products, drainage products,
thrombolytic products and venous products. More information is
available at www.angiodynamics.com. About RITA Medical Systems RITA
Medical Systems develops, manufactures and markets innovative
products that provide local oncology therapy options for cancer
patients including radiofrequency ablation (RFA) systems and
embolization products for treating cancerous tumors, as well as
percutaneous vascular and spinal access systems for systemic
treatments. The company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex�
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The company's complete line of
radiofrequency products also includes the Habib 4X resection device
and will include the new Laparoscopic Habib 4X resection device,
both of which are designed to coagulate highly vascularized tissue
to facilitate a fast dissection in order to minimize blood loss and
blood transfusion during surgery. The proprietary RITA RFA system
uses radiofrequency energy to heat tissue to a sufficiently high
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
became the first company to receive specific FDA clearance for the
palliation of pain associated with metastatic lesions involving
bone. The company also distributes LC Bead embolic microspheres in
the United States. The LC Bead microspheres are injected into
selected vessels to block the blood flow feeding a tumor, causing
it to shrink over time, and are often used in combination with RFA.
The RITA Medical Systems web site is at www.ritamedical.com.
Forward-Looking Statements This release includes �forward-looking
statements� intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. You can identify these statements by the fact that they do
not relate strictly to historical or current facts. These
statements contain words such as �may,� �will,� �predict,�
"project," �might,� �expect,� �believe,� �anticipate,� "plan,"
�intend,� "potential," �could,� �would,� "should," �estimate,�
"seek," �continue,� �pursue,� or "our future success depends," or
the negative or other variations thereof or comparable terminology.
In particular, they include statements relating to, among other
things, future actions, strategies, future performance, future
financial results of AngioDynamics and RITA and AngioDynamics'
anticipated acquisition of RITA. These forward-looking statements
are based on current expectations and projections about future
events. Investors are cautioned that forward-looking statements are
not guarantees of future performance or results and involve risks
and uncertainties that cannot be predicted or quantified and,
consequently, the actual performance or results of AngioDynamics
and RITA may differ materially from those expressed or implied by
such forward-looking statements. Such risks and uncertainties
include, but are not limited to, the following factors as well as
other factors described from time to time in our reports filed with
the Securities and Exchange Commission, including AngioDynamics'
Form 10-K for the fiscal year ended June 3, 2006 (the "Angio 2006
10-K") and Rita's Form 10-K for the year ended December 31, 2005:
financial community and rating agency perceptions of AngioDynamics
and RITA; the effects of economic, credit and capital market
conditions on the economy in general, and on medical device
companies in particular; the ability to timely and cost-effectively
integrate RITA into AngioDynamics' operations; domestic and foreign
health care reforms and governmental laws and regulations;
third-party relations and approvals, technological advances and
patents attained by competitors; and challenges inherent in new
product development, including obtaining regulatory approvals. Any
forward-looking statements are made pursuant to the Private
Securities Litigation Reform Act of 1995 and, as such, speak only
as of the date made. AngioDynamics and RITA disclaim any obligation
to update the forward-looking statements. You are cautioned not to
place undue reliance on these forward-looking statements which
speak only as of the date stated, or if no date is stated, as of
the date of this press release. Additional Information about the
Acquisition and Where to Find It In connection with AngioDynamics'
proposed acquisition of RITA (the �Acquisition�), RITA and
AngioDynamics intend to file relevant materials with the Securities
and Exchange Commission (�SEC�), including a registration statement
on Form S-4 that will contain a prospectus and a joint proxy
statement. INVESTORS AND SECURITY HOLDERS OF ANGIODYNAMICS AND RITA
ARE URGED TO READ THE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANGIODYNAMICS, RITA
AND THE ACQUISITION. The proxy statement, prospectus and other
relevant materials (when they become available), and any other
documents filed by AngioDynamics or RITA with the SEC, may be
obtained free of charge at the SEC�s web site at www.sec.gov. In
addition, investors and security holders may obtain free copies of
the documents filed with the SEC by AngioDynamics or RITA by
directing a written request to: AngioDynamics, Inc., 603 Queensbury
Avenue, Queensbury, New York 12804, Attention: Chief Financial
Officer or RITA Medical Systems, Inc., 46421 Landing Parkway,
Fremont, California 94538, Attention: Corporate Secretary.
Investors and security holders are urged to read the proxy
statement, prospectus and the other relevant materials when they
become available before making any voting or investment decision
with respect to the Acquisition. AngioDynamics, RITA and their
respective executive officers and directors may be deemed to be
participants in the solicitation of proxies from the stockholders
of RITA and AngioDynamics in connection with the Acquisition.
Information about those executive officers and directors of
AngioDynamics and their ownership of AngioDynamics common stock is
set forth in the Angio 2006 10-K, and the proxy statement for
AngioDynamics' 2006 Annual Meeting of Stockholders, which was filed
with the SEC on September 22, 2006. Information about the executive
officers and directors of RITA and their ownership of RITA common
stock is set forth in the proxy statement for RITA's 2006 Annual
Meeting of Stockholders, which was filed with the SEC on April 28,
2006. Investors and security holders may obtain additional
information regarding the direct and indirect interests of
AngioDynamics, RITA and their respective executive officers and
directors in the Acquisition by reading the proxy statement and
prospectus regarding the Acquisition when it becomes available.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. AngioDynamics, Inc. (NASDAQ:ANGO) ("AngioDynamics"), a
leading provider of medical devices for the diagnosis and treatment
of peripheral vascular diseases and other non-coronary diseases,
and RITA Medical Systems, Inc. (NASDAQ:RITA) ("RITA"), a leading
provider of medical oncology devices, today announced the signing
of a definitive agreement whereby AngioDynamics will acquire RITA
for approximately $220 million plus the assumption of approximately
$3.3 million in net debt. The transaction will create a
world-class, diversified medical technology company with a broad
line of access, diagnostic and therapeutic products that enable
interventional physicians and surgeons to treat peripheral vascular
diseases and cancerous tumors. Excluding transaction-related and
one-time integration expenses, AngioDynamics expects this
acquisition to be neutral to its fiscal year 2007 (ending June 2,
2007) earnings and to add approximately $0.05 per share to its
fiscal year 2008 (ending May 31, 2008) diluted GAAP EPS assuming
25.8 million weighted average diluted shares outstanding. The
Boards of Directors of both companies unanimously approved the
acquisition, which is anticipated to close by the end of the first
calendar quarter of 2007, subject to regulatory review, the
approval of each company's respective shareholders and other
customary closing conditions. "This business combination is about
growth, leadership and long-term value creation. The combination of
AngioDynamics and RITA will create a leader in serving the needs of
interventional radiologists, vascular surgeons and other medical
specialties with a compelling product portfolio of exciting
technologies," said Eamonn P. Hobbs, President and Chief Executive
Officer of AngioDynamics. "Interventional oncology is a large and
growing area for our existing customer base, and RITA's leadership
position, premium products and excellent reputation fit our
strategy perfectly." "RITA's talented 33-person U.S. sales force
targets the same customer base as does AngioDynamics' 52-person
U.S. sales force and the companies have virtually no product
overlap," added Mr. Hobbs. "RITA has a very strong position in
vascular access ports, which are an ideal sales fit with our
Morpheus(R) CT PICC and the vascular access port technology we
purchased from Medron last May. In addition, our recently acquired
irreversible electroporation (IRE) soft tissue ablation technology,
which AngioDynamics expects to commercialize in mid-2008, will be
complementary to RITA's diverse offering of local oncology
therapies, which include its market-leading radiofrequency ablation
systems, Habib Sealer(TM) resection devices and LC Beads(TM) for
tumor embolization." "Once the merger of our two companies is
complete, the current RITA sales organization will remain intact
and will focus on maximizing the opportunity for RITA's
radiofrequency thermal tumor ablation products and oncological
surgical devices. The current AngioDynamics sales force will take
on responsibility for RITA's specialty access catheter business,
which we believe will be a seamless transition. We also look
forward to leveraging RITA's 10-person direct sales force in the
U.K., Germany and France to sell AngioDynamics' products." Mr.
Hobbs continued, "With respect to financial performance, for the
52-weeks ended August 31, 2006 the two organizations recognized
more than $132 million in combined pro forma revenues. While we
intend to keep RITA's experienced sales, marketing, R&D and
operational teams virtually intact, we anticipate cost savings of
at least $9 million annually from the elimination of duplicate
public company, corporate and certain trade-show expenses. In
addition, we expect to receive cash tax benefits exceeding $30
million in aggregate over the next 16 years from the utilization of
RITA's federal net operating loss carry-forwards. We expect this
cash tax benefit to be approximately $1.8 million for the fiscal
year ending June 2, 2007, $7.1 million for the fiscal year ending
May 31, 2008 and $7.1 million for the fiscal year ending May 30,
2009. Clearly, this is an outstanding business opportunity for
AngioDynamics from both strategic and financial perspectives, with
very low integration risks," concluded Mr. Hobbs. Joseph DeVivo,
President and Chief Executive Officer of RITA Medical Systems,
said, "AngioDynamics has established itself as a leader in
developing, manufacturing and marketing innovative products for the
diagnosis and treatment of peripheral vascular diseases, and has
earned the respect of interventional radiologists and vascular
surgeons for its commitment to its customers. The transaction
creates compelling value for the RITA shareholders today and into
the future as RITA shareholders will become significant equity
owners of AngioDynamics and participate in its future success. I
believe having RITA become a part of AngioDynamics is the best way
to continue the vision of creating a successful franchise in
medical device oncology." Acquisition Terms Under the terms of the
merger agreement, each common share of RITA will be exchanged for
(i) 0.1722 (the "Exchange Ratio") of an AngioDynamics common share
and (ii) a specified amount of cash based on AngioDynamics' average
closing stock price for the 10-day period ending three business
days prior to the date of the shareholder meetings (the "ANGO Stock
Price"). If the ANGO Stock Price is between $18.18 and $27.29 per
share, each common share of RITA will receive an amount of cash
such that the total stock and cash consideration is equal to $4.70
per RITA share. If the ANGO Stock Price is below $18.18 per share,
RITA common shareholders will receive the equity consideration and
$1.57 in cash per RITA share. If the ANGO Stock Price is greater
than $27.29 per share, RITA shareholders will receive only the
equity consideration. All RITA outstanding options and warrants
will be exercisable for the same consideration payable to RITA
common shareholders upon exercise of the option or warrant. Based
on the Exchange Ratio, AngioDynamics expects to issue approximately
7.86 million common shares in the transaction and to issue an
additional approximately 1.91 million common shares upon exercise
of RITA options and warrants. Upon closing the transaction, it is
anticipated that RITA security holders will own approximately 34.5%
of AngioDynamics on a fully diluted treasury stock method basis.
The transaction is intended to qualify as a tax-free
reorganization. Following the closing of the transaction, the Board
of Directors of AngioDynamics will include three members of the
current RITA Board of Directors. Cain Brothers & Company, LLC
acted as exclusive financial advisor to AngioDynamics. Skadden,
Arps, Slate, Meagher & Flom LLP is acting as legal counsel to
AngioDynamics in this transaction. Piper Jaffray & Co. acted as
lead financial advisor and C.E. Unterberg, Towbin, LLC acted as
co-financial advisor to RITA in connection with the transaction.
Heller Ehrman LLP is acting as legal counsel to RITA in this
transaction. Conference Call and Presentation AngioDynamics and
RITA management will host a conference call including slide
presentation to discuss this announcement today, November 28
beginning at 11:30 a.m. Eastern time. To participate in the call,
please dial (800) 798-2801 from the U.S. or (617) 614-6205 from
outside the U.S. The passcode is 72096391. Slides that accompany
management's presentation will be available at
http://investor.angiodynamics.com/. A telephone replay of the call
will be available from 1:30 p.m. Eastern time on November 28, 2006
through 11:59 p.m. Eastern time on November 30, 2006 by dialing
(888) 286-8010 (domestic) or (617) 801-6888 (international) and
entering conference ID number 36392819. In addition, individuals
can listen to the call by visiting the investor relations portion
of the AngioDynamics web site at
http://investor.angiodynamics.com/. A recording of the call, along
with the slide presentation, will be archived there for 12 months.
About AngioDynamics AngioDynamics, Inc. is a leading provider of
innovative medical devices used by interventional radiologists,
vascular surgeons and other physicians for the minimally invasive
diagnosis and treatment of peripheral vascular disease.
AngioDynamics designs, develops, manufactures and markets a broad
line of therapeutic and diagnostic devices that enable
interventional physicians, such as interventional radiologists,
vascular surgeons and others, to treat peripheral vascular diseases
and other non-coronary diseases. The company's diverse product line
includes angiographic products and accessories, dialysis products,
vascular access products, PTA products, drainage products,
thrombolytic products and venous products. More information is
available at www.angiodynamics.com. About RITA Medical Systems RITA
Medical Systems develops, manufactures and markets innovative
products that provide local oncology therapy options for cancer
patients including radiofrequency ablation (RFA) systems and
embolization products for treating cancerous tumors, as well as
percutaneous vascular and spinal access systems for systemic
treatments. The company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The company's complete line of
radiofrequency products also includes the Habib 4X resection device
and will include the new Laparoscopic Habib 4X resection device,
both of which are designed to coagulate highly vascularized tissue
to facilitate a fast dissection in order to minimize blood loss and
blood transfusion during surgery. The proprietary RITA RFA system
uses radiofrequency energy to heat tissue to a sufficiently high
temperature to ablate it or cause cell death. In March 2000, RITA
became the first RFA company to receive specific FDA clearance for
unresectable liver lesions in addition to its previous general FDA
clearance for the ablation of soft tissue. In October 2002, RITA
became the first company to receive specific FDA clearance for the
palliation of pain associated with metastatic lesions involving
bone. The company also distributes LC Bead embolic microspheres in
the United States. The LC Bead microspheres are injected into
selected vessels to block the blood flow feeding a tumor, causing
it to shrink over time, and are often used in combination with RFA.
The RITA Medical Systems web site is at www.ritamedical.com.
Forward-Looking Statements This release includes "forward-looking
statements" intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. You can identify these statements by the fact that they do
not relate strictly to historical or current facts. These
statements contain words such as "may," "will," "predict,"
"project," "might," "expect," "believe," "anticipate," "plan,"
"intend," "potential," "could," "would," "should," "estimate,"
"seek," "continue," "pursue," or "our future success depends," or
the negative or other variations thereof or comparable terminology.
In particular, they include statements relating to, among other
things, future actions, strategies, future performance, future
financial results of AngioDynamics and RITA and AngioDynamics'
anticipated acquisition of RITA. These forward-looking statements
are based on current expectations and projections about future
events. Investors are cautioned that forward-looking statements are
not guarantees of future performance or results and involve risks
and uncertainties that cannot be predicted or quantified and,
consequently, the actual performance or results of AngioDynamics
and RITA may differ materially from those expressed or implied by
such forward-looking statements. Such risks and uncertainties
include, but are not limited to, the following factors as well as
other factors described from time to time in our reports filed with
the Securities and Exchange Commission, including AngioDynamics'
Form 10-K for the fiscal year ended June 3, 2006 (the "Angio 2006
10-K") and Rita's Form 10-K for the year ended December 31, 2005:
financial community and rating agency perceptions of AngioDynamics
and RITA; the effects of economic, credit and capital market
conditions on the economy in general, and on medical device
companies in particular; the ability to timely and cost-effectively
integrate RITA into AngioDynamics' operations; domestic and foreign
health care reforms and governmental laws and regulations;
third-party relations and approvals, technological advances and
patents attained by competitors; and challenges inherent in new
product development, including obtaining regulatory approvals. Any
forward-looking statements are made pursuant to the Private
Securities Litigation Reform Act of 1995 and, as such, speak only
as of the date made. AngioDynamics and RITA disclaim any obligation
to update the forward-looking statements. You are cautioned not to
place undue reliance on these forward-looking statements which
speak only as of the date stated, or if no date is stated, as of
the date of this press release. Additional Information about the
Acquisition and Where to Find It In connection with AngioDynamics'
proposed acquisition of RITA (the "Acquisition"), RITA and
AngioDynamics intend to file relevant materials with the Securities
and Exchange Commission ("SEC"), including a registration statement
on Form S-4 that will contain a prospectus and a joint proxy
statement. INVESTORS AND SECURITY HOLDERS OF ANGIODYNAMICS AND RITA
ARE URGED TO READ THE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANGIODYNAMICS, RITA
AND THE ACQUISITION. The proxy statement, prospectus and other
relevant materials (when they become available), and any other
documents filed by AngioDynamics or RITA with the SEC, may be
obtained free of charge at the SEC's web site at www.sec.gov. In
addition, investors and security holders may obtain free copies of
the documents filed with the SEC by AngioDynamics or RITA by
directing a written request to: AngioDynamics, Inc., 603 Queensbury
Avenue, Queensbury, New York 12804, Attention: Chief Financial
Officer or RITA Medical Systems, Inc., 46421 Landing Parkway,
Fremont, California 94538, Attention: Corporate Secretary.
Investors and security holders are urged to read the proxy
statement, prospectus and the other relevant materials when they
become available before making any voting or investment decision
with respect to the Acquisition. AngioDynamics, RITA and their
respective executive officers and directors may be deemed to be
participants in the solicitation of proxies from the stockholders
of RITA and AngioDynamics in connection with the Acquisition.
Information about those executive officers and directors of
AngioDynamics and their ownership of AngioDynamics common stock is
set forth in the Angio 2006 10-K, and the proxy statement for
AngioDynamics' 2006 Annual Meeting of Stockholders, which was filed
with the SEC on September 22, 2006. Information about the executive
officers and directors of RITA and their ownership of RITA common
stock is set forth in the proxy statement for RITA's 2006 Annual
Meeting of Stockholders, which was filed with the SEC on April 28,
2006. Investors and security holders may obtain additional
information regarding the direct and indirect interests of
AngioDynamics, RITA and their respective executive officers and
directors in the Acquisition by reading the proxy statement and
prospectus regarding the Acquisition when it becomes available.
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended.
Rita Medical (NASDAQ:RITA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rita Medical (NASDAQ:RITA)
Historical Stock Chart
From Jul 2023 to Jul 2024